November 18, 2026
Health news, explained with evidence
LIVE

Omalizumab Shows Promise in Preventing Severe Reactions in Alpha-Gal Syndrome

🔬 Research 2 min read 👁 9

A case series presented at the ACAAI annual meeting suggests that the biologic drug omalizumab may help eliminate anaphylaxis risks in patients with red meat allergies, though experts urge caution.

Omalizumab Shows Promise in Preventing Severe Reactions in Alpha-Gal Syndrome🔬Research

Photo: medpagetoday.com

Key points

  • A study of 64 high-risk alpha-gal syndrome patients found no episodes of anaphylaxis while on omalizumab.
  • About 33 percent of participants were able to partially or fully reintroduce mammalian meat into their diets.
  • Researchers emphasize that the treatment is not a cure and alpha-gal syndrome remains unpredictable.

Treatment with the biologic drug omalizumab, widely known as Xolair, was linked to the elimination of anaphylaxis in a cohort of patients suffering from alpha-gal syndrome, a tick-borne allergy to mammalian meat and products. The findings were detailed at the American College of Allergy, Asthma & Immunology annual meeting by lead investigator Collette M. Tilly, MD, of the University of North Carolina at Chapel Hill.

The retrospective study reviewed 64 high-risk patients who experienced severe allergic symptoms from red meat despite strict avoidance. Before starting treatment, more than half of the cohort had required epinephrine to treat presumed reactions. While taking the medication—with a median duration of nearly two years—none of the participants experienced anaphylaxis. Furthermore, 95 percent reported improvements in symptom frequency or severity, and roughly a third were able to partially or fully reintroduce mammalian products into their diets.

Experts emphasize that the findings are observational and stem from a single-center case series rather than a randomized clinical trial, meaning the data remain early-stage. Omalizumab lowers circulating immunoglobulin E (IgE), the antibody responsible for triggering allergic responses, but researchers caution that the therapy does not act as a cure or guarantee complete safety against unexpected exposures. Because alpha-gal syndrome is notoriously unpredictable and often relies on secondary co-factors like fat content or portion size, strict avoidance remains the official recommendation.

What to know: While omalizumab is approved for IgE-mediated food allergies, its use for alpha-gal syndrome requires careful medical oversight. Always consult a qualified healthcare professional before making any changes to your diet or treatment plan.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/acaai/123890 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.